Sanofi Sells Smallpox Vaccine to Emergent

Source: Emergent Biosolutions

Jul 18, 2017

Emergent BioSolutions has entered into an agreement to acquire Smallpox vaccine ACAM2000 from Sanofi in an all-cash transaction with a total value of up to $125 million. The deal consists of $97.5 million upfront and up to $27.5 million in contingent milestones.

ACAM2000 is the only FDA-licensed smallpox vaccine and this deal will see Emergent assume responsibility for Sanofi's existing CDC contract. The contract holds a remaining value of up to approximately $160 million for deliveries of ACAM2000 to the Strategic National Stockpile.

Read the Emergent release